Efficacy of a Risk-Based Letermovir Use Strategy in CMV-Positive Recipients of Allogeneic HCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
Blood Adv 2022 Nov 09;[EPub Ahead of Print], M Sourisseau, E Faure, H Béhal, P Chauvet, M Srour, A Capes, V Coiteux, L Magro, S Alfandari, EK Alidjinou, N Simon, F Vuotto, M Karam, K Faure, I Yakoub-Agha, D BeauvaisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.